FDA approves everolimus (a rapalog) for treatment of various diseases, such as renal cell carcinoma, progressive neuroendocrine tumors of pancreatic origin (PNET), postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, tuberous sclerosis complex (TSC)-associated partial-onset seizures, TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma. The gene discussed is ERBB2; the disease is tuberous sclerosis.